Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Completed 3Terminated 2

Sponsor Class

OTHER 88NIH 15NETWORK 5INDUSTRY 3

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Lymphoma 24Leukemia 18Sarcoma 17Neuroblastoma 13Central Nervous System Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Hodgkin Disease 9Breast Neoplasms 9Brain Neoplasms 9Burkitt Lymphoma 7Malignant mesenchymal tumor 6Lymphoma, Large B-Cell, Diffuse 6Leukemia, Myeloid, Acute 6Leukemia, Monocytic, Acute 6Rhabdomyosarcoma 5Ovarian Neoplasms 5Multiple Myeloma 5Leukemia, Myelomonocytic, Acute 5Leukemia, Megakaryoblastic, Acute 5Leukemia, Erythroblastic, Acute 5Kidney Neoplasms 5Testicular Neoplasms 4Teratoma 4Neutropenia 4Neuroectodermal Tumors, Primitive, Peripheral 4Medulloblastoma 4Lung Neoplasms 4Leukemia, Biphenotypic, Acute 4Endometrial Neoplasms 4Dendritic Cell Sarcoma, Interdigitating 4

Interventions

Dexamethasone 45Bortezomib 21Lenalidomide 19Cyclophosphamide 19daratumumab 16Calcium Dobesilate 13Thalidomide 12Melphalan 11carfilzomib 9Prednisone 7pomalidomide 6Peripheral Blood Stem Cell Transplantation 6Doxorubicin 6Filgrastim 5dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4Vincristine 4isatuximab 3Interferon-alpha 3Etoposide 3selinexor 2sargramostim 2ixazomib 2elotuzumab 2cobimetinib 2Steroids 2Radiotherapy 2Microarray Analysis 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
NETWORK × Multiple Myeloma × Filgrastim × Clear all
NCT00003353 2023-06-22

High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis

Eastern Cooperative Oncology Group

Phase 2 Completed
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00052884 2023-06-18

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Eastern Cooperative Oncology Group

Phase 1 Terminated
8 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

NCT00064337 2018-08-09

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

SWOG Cancer Research Network

Phase 2 Completed
104 enrolled 6 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

NCT00040937 2016-12-08

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

SWOG Cancer Research Network

Phase 2 Completed
147 enrolled 6 charts
Plasma cell

Multiple Myeloma

NCT00005834 2015-03-06

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

SWOG Cancer Research Network

Phase 3 Terminated
19 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡